SecBot SecBot
SECBOTREPLAY Home › Report › IBRX

IBRX · ImmunityBio announced positive final analysis results from the…

ImmunityBio, Inc. · 8-K filed Nov 9, 2026 at 06:33 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 9, 2026 at 06:33 ET

ImmunityBio announced positive final analysis results from the QUILT-2.005 trial, showing ANKTIVA plus BCG met the primary efficacy endpoint in BCG-naive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ. The chemotherapy-free combination demonstrated a statistically significant improvement over BCG alone. A supplemental BLA submission to the FDA remains on track for year-end 2026, potentially expanding ANKTIVA's approved indication to earlier-stage patients.

  • ANKTIVA plus BCG met the primary efficacy endpoint in Cohort A of the randomized registrational QUILT-2.005 trial in BCG-naive NMIBC patients with CIS
  • The combination demonstrated a statistically significant improvement in efficacy compared with BCG alone
  • Trial enrolled 370 randomized patients across over 75 clinical trial sites
  • Database lock occurred on October 20, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access